OJU  Vol.5 No.6 , June 2015
Completion of Maintenance Bacillus Calmette-Guerin Therapy Might Prolong Recurrence-Free Survival in Patients with Non Muscle Invasive Bladder Cancer
Abstract: Objective: The aim of our study was to compare recurrence-free survival between patients who completed treatment with maintenance Bacillus Calmette-Guerin (BCG) and patients who did not complete the planned treatment. Materials and Methods: Data on 115 patients with intermediate- and high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who were treated with BCG were available for analysis. Patients were categorized into 4 groups based on treatment duration: patients who completed three years of maintenance treatment, patients who stopped treatment while on maintenance, patients who were still on-treatment and patients who were treated with induction course only. Results: Of 115 patients, 86 were men and 29 were women with mean age of 67.8 (range 40 - 93) years. 51% had high-grade tumors and 49% had low-grade tumors. Seventy-three patients (63%) had multiple tumors. Thirty patients (26%) were treated with induction-only, 18 patients (16%) are on-treatment, 14 patients (12%) finished maintenance protocol and 53 patients (46%) discontinued treatment. Reasons for stopping treatment were disease recurrence in 13 patients and toxicity in 40 patients. 5-year recurrence-free survival was 100%, 63%, 60% and 56% in patients who completed maintenance treatment, stopped during maintenance treatment, were on-treatment and those who received induction only therapy, respectively. Conclusions: Patients should be encouraged to adhere to maintenance BCG treatment because of its favorable effect on recurrence-free survival probability.
Cite this paper: Bahouth, Z. , Masarwa, I. , Nativ, O. and Halachmi, S. (2015) Completion of Maintenance Bacillus Calmette-Guerin Therapy Might Prolong Recurrence-Free Survival in Patients with Non Muscle Invasive Bladder Cancer. Open Journal of Urology, 5, 77-83. doi: 10.4236/oju.2015.56012.

[1]   Bohle, A., Jocham, D. and Bock, P.R. (2003) Intravesical Bacillus Calmette-Guerin versus Mitomycin C for Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity. The Journal of Urology, 169, 90-95.

[2]   Han, R.F. and Pan, J.G. (2006) Can Intravesical Bacillus Calmette-Guérin Reduce Recurrence in Patients with Superficial Bladder Cancer? A Meta-Analysis of Randomized Trials. Urology, 67, 1216-1223.

[3]   Malmström, P.-U., Sylvester, R.J., Crawford, D.E., Friedrich, M., Krege, S., Rintala, E., et al. (2009) An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non-Muscle-Invasive Bladder Cancer. European Urology, 56, 247-256.

[4]   Brausi, M., Witjes, J.A., Lamm, D., Persad, R., Palou, J., Colombel, M., et al. (2011) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. The Journal of Urology, 186, 2158-2167.

[5]   Lamm, D., Colombel, M., Persad, R., Soloway, M., Böhle, A., Palou, J., et al. (2008) Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer. European Urology Supplements, 7, 651-666.

[6]   Montie, J.E., Clark, P.E., Eisenberger, M.A., El-Galley, R., Greenberg, R.E., Herr, H.W., et al. (2009) Bladder Cancer. Journal of the National Comprehensive Cancer Network, 7, 8-39.

[7]   Sylvester, R.J., van der Meijden, A.P.M. and Lamm, D.L. (2002) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-Analysis of the Published Results of Randomized Clinical Trials. The Journal of Urology, 168, 1964-1970.

[8]   Herr, H.W., Dalbagni, G. and Donat, S.M. (2011) Bacillus Calmette-Guérin without Maintenance Therapy for High- Risk Non-Muscle-Invasive Bladder Cancer. European Urology, 60, 32-36.

[9]   Lamm, D.L., Blumestein, B.A., Crissman, J.D., Montie, J.E., Gottesman, J.E., Lowe, B.A., et al. (2000) Maintenance Bacillus Calmette-Guerin Immunotherapy for Recurrent TA, T1 and Carcinoma in Situ Transitional Cell Carcinoma of the Bladder: A Randomized Southwest Oncology Group Study. The Journal of Urology, 163, 1124-1129.

[10]   Trotti, A., Colevas, A.D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003) CTCAE v3.0: Development of a Comprehensive Grading System for the Adverse Effects of Cancer Treatment. Seminars in Radiation Oncology, 13, 176-181.

[11]   Sylvester, R.J., van der Meijden, A.P.M., Oosterlinck, W., Witjes, J.A., Bouffioux, C., Denis, L., et al. (2006) Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology, 49, 466-477.

[12]   Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2013) Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High- Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-Third Dose versus Full Dose and 1 Year versus 3 Years of Maintenance. European Urology, 63, 462-472.

[13]   Zlotta, A.R., van Vooren, J.P., Huygen, K., Drowart, A., Decock, M., Pirson, M., et al. (2000) What Is the Optimal Regimen for BCG Intravesical Therapy? Are Six Weekly Instillations Necessary? European Urology, 37, 470-477.

[14]   Van der Meijden, A.P.M., Sylvester, R.J., Oosterlinck, W., Hoeltl, W. and Bono, A.V. (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. European Urology, 44, 429-434.

[15]   Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2014) Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology, 65, 69-76.